← Oncology Approval Tracker

FDA DECISION ·

Rytelo

imetelstat · Geron

FDA approvalNew therapyMyelodysplastic syndromes
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with low- to intermediate-1-risk myelodysplastic syndromes and transfusion-dependent anemia requiring at least four red-cell units in eight weeks, after inadequate or lost ESA response or when an ESA is unsuitable.

LAMPGEN ANALYSIS

Why it matters

The telomerase inhibitor offers an option centered on reducing transfusion dependence in a defined lower-risk MDS group.

What research teams should watch

Reconcile transfusions across hospitals to confirm the qualifying eight-week window and track cytopenias and transfusion-free intervals.

PRIMARY RECORDS

Sources